Experiments point to new treatments for PKD

A family of small molecules called CFTR inhibitors show promising effects in slowing the progression of polycystic kidney disease (PKD), the most common genetic disease of the kidneys, according to preliminary research reported in the July 2008 issue of the Journal of the American Society Nephrology.

Although much more study is needed, CFTR inhibitors could provide a useful new approach for the treatment of PKD. "The CFTR inhibitors could be the basis of a lifelong treatment to slow renal cyst growth and decline in renal function, prolonging dialysis-free patient survival," comments Dr. Alan S. Verkman of University of California, San Francisco, School of Medicine.

Patients with PKD develop cysts on the kidneys, which progressively increase in size and number. The kidneys become enlarged, eventually leading to kidney failure. Previous research has suggested that the buildup of fluid in the cysts is related to chloride secretion, which is affected by the CFTR (cystic fibrosis transmembrane conductance regulator) gene. The researchers used automated "high-throughput" screening techniques to identify CFTR inhibitors that might affect cyst growth.

These screening studies identified two classes of small-molecule CFTR inhibitors that slowed the growth of renal cysts. The best inhibitor of each class was identified and shown to reduce the number and growth of cysts by more than 80 percent.

The inhibitors were then tested in mice that had been genetically altered to produce a condition similar to PKD. Animals treated with CFTR inhibitors for up to seven days had significantly slower cyst expansion and kidney enlargement, and better preservation of kidney function. There was no evidence of harmful effects on kidney function.

PKD is an incurable condition for which new treatments are urgently needed. If effective medications to reduce the rate of fluid buildup in cysts could be developed, they might provide an entirely new approach to treatment to slowing the progression of the disease.

The results show that CFTR plays a role in the growth of renal cysts, and suggest that CFTR inhibitors have potential as treatments to reduce cyst growth in PKD. However, much more research will be needed to see if drugs based on the CFTR blockers will be useful in human PKD.

"The mouse model of PKD is not the real human disease for many reasons, such as the more rapid progression of disease in mice," says Dr. Verkman. "Clinical trials will be needed to determine the efficacy of these compounds in human PKD."

Source: American Society of Nephrology

Related stories:

Researchers discover cell's 'quality control' mechanism
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells – sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.
In Poland, Chopin's heart may hold secret of his death
The heart of Frederic Chopin, one of the world's most cherished musical geniuses, could hold the secret to his untimely death.
Computer simulations point to key molecular basis of cystic fibrosis
Researchers from the University of North Carolina at Chapel Hill have identified a key molecular mechanism that may account for the development of cystic fibrosis, which about 1 in 3000 children are born with in the US every year. The findings, published February 29 in the open-access journal PLoS Computational Biology, add new knowledge to understanding the development of this disease and may also point the way to new corrective treatments.
Peptide discovered in scorpion venom may hold key to secretory diseases
Researchers have discovered a peptide in scorpion venom that may hold the key to understanding and controlling cystic fibrosis and other secretory diseases.
Secondhand smoke exposure is linked to worsening of lung function for persons with cystic fibrosis
Exposure to secondhand smoke is associated with adverse effects on lung function among persons with cystic fibrosis, with this effect being worse for persons with certain gene variations, according to a study in the January 30 issue of JAMA.
Technology reveals 'lock and key' proteins behind diseases
A new technology developed at the University of Toronto is revealing biochemical processes responsible for diseases such as cystic fibrosis and could one day pave the way for pharmaceutical applications.
Software, evolution and micro-inversions -- improving the building of phylogenetic trees
Biologists will be able to reconstruct the process of evolution, determine relationships between species and build phylogenetic trees with greater accuracy thanks to a new method for identifying “microinversions,” which are extremely short strings of inverted nucleotides.
This new work from researchers at UC San Diego and Brown University will appear in the online version of PNAS on December 18, 2006.

News discussion:

Medicine & Health news